Share on LinkedInShare on LinkedIn

ARTICLE · 22 JUNE 2021

Third Circuit Recognizes Catch-22 Situation In Pleading Trade Secret Misappropriation

A trade secret case involving pharmaceutical technology has finally moved past the pleading stage after four iterations of the complaint and an appeal...

United StatesIntellectual Property

A trade secret case involving pharmaceutical technology has finally moved past the pleading stage after four iterations of the complaint and an appeal, providing some key takeaways and insights into bringing trade secret misappropriation claims under the Defend Trade Secrets Act (DTSA).

In 2017, Oakwood Laboratories (Oakwood) filed a lawsuit in the New Jersey district court alleging that its former employee Dr. Bagavathikanun Thanoo and competitor Aurobindo Pharma (Aurobindo) misappropriated certain trade secrets. The alleged trade secrets pertain to a microsphere technology, which Oakwood claims to have used to design certain difficult-to-develop peptide drug products. On the defendants' motion, the district court dismissed the complaint and its subsequent amended versions a total of four times, every time demanding more specificity and precision as to: (i) which trade secret was alleged to be misappropriated; (ii) how the alleged misappropriation occurred; and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from